Junichi Sugai

926 total citations · 1 hit paper
19 papers, 639 citations indexed

About

Junichi Sugai is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Junichi Sugai has authored 19 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 9 papers in Dermatology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Junichi Sugai's work include Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (9 papers) and Autoimmune Bullous Skin Diseases (3 papers). Junichi Sugai is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (9 papers) and Autoimmune Bullous Skin Diseases (3 papers). Junichi Sugai collaborates with scholars based in Japan, Australia and France. Junichi Sugai's co-authors include Mamitaro Ohtsuki, Mayumi Komine, Megumi Kishimoto, Koji Kamiya, Makiko Mieno, Muneo Ohkido, Akira Ozawa, Yo Kawakubo, Akira Ozawa and Kowichi Jimbow and has published in prestigious journals such as International Journal of Molecular Sciences, Journal of Clinical Medicine and Journal of Dermatological Science.

In The Last Decade

Junichi Sugai

18 papers receiving 628 citations

Hit Papers

Risk Factors for the Development of Psoriasis 2019 2026 2021 2023 2019 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junichi Sugai Japan 9 496 293 94 85 71 19 639
Ignasi Pau‐Charles Spain 9 330 0.7× 240 0.8× 93 1.0× 65 0.8× 49 0.7× 21 488
Shiu-chung Au United States 10 425 0.9× 282 1.0× 103 1.1× 101 1.2× 69 1.0× 22 639
Jacqueline Greb United States 7 573 1.2× 341 1.2× 158 1.7× 94 1.1× 85 1.2× 10 776
Gleison Vieira Duarte Brazil 13 459 0.9× 254 0.9× 78 0.8× 66 0.8× 38 0.5× 29 630
Maya Debbaneh United States 13 399 0.8× 232 0.8× 115 1.2× 82 1.0× 70 1.0× 16 582
Jennifer Soung United States 15 590 1.2× 562 1.9× 60 0.6× 140 1.6× 54 0.8× 45 952
A.V. Anstey United Kingdom 11 489 1.0× 430 1.5× 103 1.1× 65 0.8× 28 0.4× 21 897
Ivan Grozdev Bulgaria 12 292 0.6× 196 0.7× 56 0.6× 34 0.4× 29 0.4× 19 480
Huiqun Ma China 8 250 0.5× 159 0.5× 71 0.8× 53 0.6× 44 0.6× 14 389
Deepak Balak Netherlands 13 241 0.5× 152 0.5× 78 0.8× 23 0.3× 40 0.6× 30 435

Countries citing papers authored by Junichi Sugai

Since Specialization
Citations

This map shows the geographic impact of Junichi Sugai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junichi Sugai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junichi Sugai more than expected).

Fields of papers citing papers by Junichi Sugai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junichi Sugai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junichi Sugai. The network helps show where Junichi Sugai may publish in the future.

Co-authorship network of co-authors of Junichi Sugai

This figure shows the co-authorship network connecting the top 25 collaborators of Junichi Sugai. A scholar is included among the top collaborators of Junichi Sugai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junichi Sugai. Junichi Sugai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
2.
Kishimoto, Megumi, Mayumi Komine, Koji Kamiya, et al.. (2023). Four‐year drug survival of apremilast in patients with psoriasis. The Journal of Dermatology. 50(7). 960–963. 3 indexed citations
3.
Kishimoto, Megumi, Mayumi Komine, Koji Kamiya, et al.. (2023). Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study. Dermatology and Therapy. 13(6). 1347–1360. 3 indexed citations
4.
Kamiya, Koji, Megumi Kishimoto, Aya Kuwahara, et al.. (2023). Single‐center survey of incidental imaging findings on computed tomography in patients with psoriasis on biologic therapy. The Journal of Dermatology. 50(8). 1045–1051. 1 indexed citations
6.
Kamiya, Koji, Megumi Kishimoto, Takeo Maekawa, et al.. (2021). Single‐center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic. The Journal of Dermatology. 48(12). 1907–1912. 3 indexed citations
7.
Kishimoto, Megumi, Mayumi Komine, Tuba M. Ansary, et al.. (2021). STAT3 Activation in Psoriasis and Cancers. Diagnostics. 11(10). 1903–1903. 17 indexed citations
8.
Nakase, Keisuke, Yuki Horiuchi, Miki Tanioka, et al.. (2020). Characterization of acne patients carrying clindamycin‐resistant Cutibacterium acnes: A Japanese multicenter study. The Journal of Dermatology. 47(8). 863–869. 21 indexed citations
9.
Kishimoto, Megumi, Mayumi Komine, Koji Kamiya, Junichi Sugai, & Mamitaro Ohtsuki. (2019). Drug survival of apremilast in a real‐world setting. The Journal of Dermatology. 46(7). 615–617. 20 indexed citations
10.
Kishimoto, Megumi, Mayumi Komine, Koji Kamiya, et al.. (2019). Drug survival of biologic agents for psoriatic patients in a real‐world setting in Japan. The Journal of Dermatology. 47(1). 33–40. 44 indexed citations
11.
Kamiya, Koji, Megumi Kishimoto, Junichi Sugai, Mayumi Komine, & Mamitaro Ohtsuki. (2019). Risk Factors for the Development of Psoriasis. International Journal of Molecular Sciences. 20(18). 4347–4347. 396 indexed citations breakdown →
12.
Kamiya, Koji, Masaru Karakawa, Mayumi Komine, et al.. (2019). Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution. The Journal of Dermatology. 46(3). 199–205. 7 indexed citations
13.
Kishimoto, Megumi, et al.. (2018). Real‐world use of apremilast for patients with psoriasis in Japan. The Journal of Dermatology. 45(11). 1345–1348. 25 indexed citations
14.
Karakawa, Masaru, Mayumi Komine, Megumi Kishimoto, et al.. (2016). Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. The Journal of Dermatology. 43(11). 1354–1357. 7 indexed citations
15.
Ohtsuki, Mamitaro, Hidemi Nakagawa, Junichi Sugai, et al.. (2003). Long‐Term Continuous versus Intermittent Cyclosporin: Therapy for Psoriasis. The Journal of Dermatology. 30(4). 290–298. 27 indexed citations
16.
Ozawa, Akira, Yasuo Haruki, K. Iwashita, et al.. (1999). Follow‐up of Clinical Efficacy of Iontophoresis Therapy for Postherpetic Neuralgia (PHN). The Journal of Dermatology. 26(1). 1–10. 7 indexed citations
17.
Sugai, Junichi, Yo Kawakubo, Akira Ozawa, et al.. (1998). Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. Journal of Dermatological Science. 17(2). 85–92. 19 indexed citations
18.
Sugai, Junichi, et al.. (1998). New method for determining prognosis of patients with psoriasis (E-PAP). Journal of Dermatological Science. 16(2). 165–169. 5 indexed citations
19.
Ozawa, Akira, Junichi Sugai, Yo Kawakubo, et al.. (1998). HLA Class I and II Alleles and Susceptibility to Generalized Pustular Psoriasis: Significant Associations with HLA‐Cw1 and HLA‐DQB1*0303. The Journal of Dermatology. 25(9). 573–581. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026